Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.
Future Oncol
; 17(4): 471-486, 2021 Feb.
Article
em En
| MEDLINE
| ID: mdl-33094641
ABSTRACT
Clinical trial and real-world data in non-small-cell lung cancer indicate that 10-60% of patients that progressed on first- or second-generation EGFR-targeting tyrosine kinase inhibitors (TKI) do not receive systemic second-line therapy. In our article, we discuss efficacy, safety and treatment duration with different EGFR-TKIs and stress the need for delivery of the most efficacious therapy in the first-line. We also provide our perspective on analysis of circulating tumor DNA and the role of EGFR-TKI in combined therapies. Finally, we review new therapeutic options to overcome resistance to EGFR-TKI. We believe that overall treatment duration and access to different medications in subsequent lines of therapy should be considered when planning the optimal treatment strategy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pacientes Desistentes do Tratamento
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Neoplasias Pulmonares
/
Mutação
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article